Last reviewed · How we verify

Vehicle of KPI-121 1.0%

Kala Pharmaceuticals, Inc. · Phase 3 active Small molecule

Vehicle of KPI-121 1.0% is a corticosteroid Small molecule drug developed by Kala Pharmaceuticals, Inc.. It is currently in Phase 3 development for Treatment of non-infectious uveitis. Also known as: Vehicle of KPI-121 1.0% Ophthalmic Suspension.

KPI-121 is a corticosteroid

KPI-121 is a corticosteroid Used for Treatment of non-infectious uveitis.

At a glance

Generic nameVehicle of KPI-121 1.0%
Also known asVehicle of KPI-121 1.0% Ophthalmic Suspension
SponsorKala Pharmaceuticals, Inc.
Drug classcorticosteroid
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

KPI-121 is a corticosteroid that is being investigated for its potential to treat various inflammatory conditions. Corticosteroids are a class of steroid hormones that are produced by the adrenal gland and play a crucial role in regulating inflammation and immune responses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vehicle of KPI-121 1.0%

What is Vehicle of KPI-121 1.0%?

Vehicle of KPI-121 1.0% is a corticosteroid drug developed by Kala Pharmaceuticals, Inc., indicated for Treatment of non-infectious uveitis.

How does Vehicle of KPI-121 1.0% work?

KPI-121 is a corticosteroid

What is Vehicle of KPI-121 1.0% used for?

Vehicle of KPI-121 1.0% is indicated for Treatment of non-infectious uveitis.

Who makes Vehicle of KPI-121 1.0%?

Vehicle of KPI-121 1.0% is developed by Kala Pharmaceuticals, Inc. (see full Kala Pharmaceuticals, Inc. pipeline at /company/kala-pharmaceuticals-inc).

Is Vehicle of KPI-121 1.0% also known as anything else?

Vehicle of KPI-121 1.0% is also known as Vehicle of KPI-121 1.0% Ophthalmic Suspension.

What drug class is Vehicle of KPI-121 1.0% in?

Vehicle of KPI-121 1.0% belongs to the corticosteroid class. See all corticosteroid drugs at /class/corticosteroid.

What development phase is Vehicle of KPI-121 1.0% in?

Vehicle of KPI-121 1.0% is in Phase 3.

What are the side effects of Vehicle of KPI-121 1.0%?

Common side effects of Vehicle of KPI-121 1.0% include Increased intraocular pressure.

Related